Table 3 Characteristic collected from included studies
Studies | Method | Studied groups | Methylation status | Potential Clinical Value | ||
|---|---|---|---|---|---|---|
NT | BTLs | DTCs | ||||
Venkataraman et al. (1999) | MSP | NT (5), PTC (16), FTC (2) | 2/5 | – | 8/18 | Chemical demethylation therapy |
Neuman et al. (2004) | MSP | ST (14), CTN (14) | 0/14 | – | 6/14 | Could be a regulatory mechanism of NIS transcription |
Smith et al. (2007) | MSP | Controls (FA (10), goiters (15), normal thyroids (2)), PTC (32) | 0 | 0 | 7/32 | Marker of virulence |
Stephen et al. (2011) | MSP | NT (5), hyperthyroid (3), PTC (11), FTC (2) | 1/5 | 1/3 | 7/13 | Early event |
Galrão et al. (2013) | SQ-MSP | BTLs (10), PTC (18), FTC (2) | – | 2.23 | 1.92 | Very frequent event |
Galrão et al. (2014) | BSP | BTLs (10), PTC (18), FTC (2) | – | 23.2% | 66.1% | Early event |
Choi et al. (2014) | BSP and MSP | NT (24), PTC (24) | 29% | – | 58% | Related to BRAF (V600E) mutation |
Stephen et al. (2015) | QMSP | ANT (24), FTC-Hurthle (26), FTC-Classic (27) |  > 0.0 | – |  > 0.0 | Early changes in thyroid tumorigenesis regardless of cell type |
Stephen et al. (2018) | QMSP | NT (71), FA (83), PTC (85), FTC (90) | 0.001(0.002) | 0.014 (0.041) | PTC (0.009(0.027)) FTC (0.02(0.07)) | – |